| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
10.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
10.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors in cells transfected with control or Stat3 siRNA |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors in cells transfected with control or Stat3 siRNA |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Supression of tumor supporting factors in cells transfected with control or Stat3 siRNA |
Western Blot |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
in cells overexpressing KLF8 |
BioCoat invasion chamber assay |
10.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
in cells overexpressing KLF8 |
BioCoat invasion chamber assay |
5.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- WC |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
p-STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- WC |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- WC |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- WC |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- WC |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Cyto |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
p-STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Cyto |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Cyto |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Cyto |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Cyto |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Nuc |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
p-STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Nuc |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
STAT3 |
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Nuc |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Nuc |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Immunoblotting analysis (whole cell- WC; cytoplasmic- Cyto; nuclear- Nuc) |
Western Blot- Nuc |
15.00 µM |
MDA-MB-231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
10.00 µM |
231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
20.00 µM |
231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
30.00 µM |
231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell migration |
Wound healing assay |
10.00 µM |
231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell migration |
Wound healing assay |
15.00 µM |
231 |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
10.00 µM |
231/St3C |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
20.00 µM |
231/St3C |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Influence on cell viability and proliferation |
CyQUANT cell proliferation assay |
30.00 µM |
231/St3C |
Homo sapiens |
|
|
|
| BP-1-102/ 17o |
Antitumor effect |
Tumor size |
1.00 mg/kg |
MDA-MB-231 (xenograft) |
Mus musculus |
|
|
|
| BP-1-102/ 17o |
Antitumor effect |
Tumor size |
3.00 mg/kg |
MDA-MB-231 (xenograft) |
Mus musculus |
|
|
|
